9 completed, 2 withdrawn. 5 Phase 2, 4 Phase 1, 3 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 5 |
| Phase 1 | 4 | Completed 3, Withdrawn 1 |
| Phase 3 | 3 | Completed 3 |
| Phase 4 | 1 | Withdrawn 1 |
Follow Antares Pharma Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testosterone Treatment for Erectile Dysfunction and Multiple Sclerosis XYOSTED 75 milligram (mg) in 0.5 ML Auto-Injector - Multiple Sclerosis, Erectile Dysfunction | Phase 4 | Withdrawn | Tulane University | 2026-06-01 | 2026-10-02 | |
| Phase 1 Study of ATRS-2002 in Healthy Male Adults Abiraterone Acetate - Metastatic Castration-resistant Prostate Cancer | Phase 1 | Withdrawn | Syneos Health | 2022-09-01 | 2023-04-28 | |
| Safety of Subcutaneous Testosterone Enanthate in Adult Male Hypogonadism Testosterone enanthate auto-injector - Hypogonadism | Phase 2 | Completed | Antares Pharma Inc. | 66 | 2016-06-01 | 2018-03-22 |
| Subcutaneous Testosterone Enanthate Safety in Adult Men Diagnosed With Hypogonadism Testosterone enanthate auto-injector - Hypogonadism | Phase 3 | Completed | Antares Pharma Inc. | 133 | 2015-07-01 | 2018-03-30 |
| Pharmacokinetic Study of Subcutaneous Testosterone Enanthate Testosterone enanthate auto-injector - Hypogonadism | Phase 1 | Completed | Antares Pharma Inc. | 12 | 2014-09-01 | 2019-04-19 |
| Subcutaneous Testosterone Replacement Efficacy and Safety in Adult Men Diagnosed With Hypogonadism Testosterone enanthate auto-injector - Hypogonadism | Phase 3 | Completed | Antares Pharma Inc. | 150 | 2014-07-01 | 2018-02-07 |
| Pharmacokinetic Study of Testosterone Enanthate QuickShot™ - 50 mg Treatment B, QuickShot™ - 100 mg Treatment A, Delatestryl 200 mg IM Treatment C - Hypogonadism | Phase 1 / Phase 2 | Completed | Antares Pharma Inc. | 39 | 2013-09-01 | 2018-01-11 |
| Comparison of Methotrexate (MTX) and the VIBEX™ MTX Device MTX - Rheumatoid Arthritis (RA) | Phase 2 | Completed | Antares Pharma Inc. | 49 | 2012-05-01 | 2014-05-19 |
| Actual Human Use of Methotrexate (MTX) Subcutaneously Administered Via the VIBEX™ MTX Auto-Injector Device VIBEX MTX - Rheumatoid Arthritis (RA) | Phase 2 | Completed | Antares Pharma Inc. | 101 | 2012-05-01 | 2014-04-30 |
| Exposure Study Comparing 3 Routes of Methotrexate (MTX) Administration Methotrexate (MTX) - Rheumatoid Arthritis | Phase 1 / Phase 2 | Completed | Antares Pharma Inc. | 38 | 2011-01-01 | 2014-02-25 |
| Study of Topically Administered Oxybutynin Gel in Patients With Urge Incontinence Oxybutynin, Placebo - Urge Urinary Incontinence, Urinary Frequency | Phase 3 | Completed | Antares Pharma Inc. | 626 | 2009-03-01 | 2014-07-02 |
Hypogonadism (5) · Arthritis, Rheumatoid (3) · Erectile Dysfunction (1) · Multiple Sclerosis (1) · Urinary Incontinence, Urge (1)
Testosterone (4) · testosterone enanthate (4) · Abiraterone Acetate (1) · Methotrexate (1) · Tolterodine Tartrate (1) · oxybutynin (1)
United States (10)
Alan J Kivitz, MD;CPI (3) · Gary Bedel, MD (2) · Jed Kaminetsky, MD (2) · Jonathan Jaffe, MD (1) · Omar A Raheem, MD (1)